Compare · LFCR vs LLY
LFCR vs LLY
Side-by-side comparison of Lifecore Biomedical Inc. (LFCR) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LFCR and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.11T, about 6325.6x LFCR ($175.5M).
- Over the past year, LFCR is down 37.5% and LLY is up 52.7% - LLY leads by 90.2 points.
- LLY has been more active in the news (11 items in the past 4 weeks vs 2 for LFCR).
- LLY has more recent analyst coverage (25 ratings vs 6 for LFCR).
- Company
- Lifecore Biomedical Inc.
- Eli Lilly and Company
- Price
- $4.68-5.26%
- $1178.57+0.73%
- Market cap
- $175.5M
- $1.11T
- 1M return
- -12.85%
- +5.00%
- 1Y return
- -37.52%
- +52.71%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 2
- 11
- Recent ratings
- 6
- 25
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest LFCR
- Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Lifecore Biomedical Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Lifecore Biomedical Signs New Agreement with Global Pharmaceutical Company
- Director Kiper Christopher S was granted 25,907 shares (SEC Form 4)
- Director Obus Nelson was granted 25,907 shares, increasing direct ownership by 19% to 164,100 units (SEC Form 4)
- Director Aryeh Jason was granted 25,907 shares, increasing direct ownership by 59% to 69,967 units (SEC Form 4)
- Director Korenberg Matthew E was granted 25,907 shares, increasing direct ownership by 59% to 69,967 units (SEC Form 4)
- Director Schechter Joshua was granted 25,907 shares, increasing direct ownership by 24% to 133,080 units (SEC Form 4)
- Director Antunes Humberto Calheiros was granted 25,907 shares, increasing direct ownership by 55% to 72,967 units (SEC Form 4)
- Director Johnson Paul Harold was granted 25,907 shares, increasing direct ownership by 59% to 69,967 units (SEC Form 4)
Latest LLY
- Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time
- Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
- Three Biotechs Deliver Catalysts to Watch
- A Nasdaq-Listed Regenerative Tissue Company Just Opened a Lab: The Next Step in Scaling a Platform Built for a NEW Aesthetics Opportunity
- Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China
- Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy
- What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management
- Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
- SEC Form 11-K filed by Eli Lilly and Company
- Lilly declares third-quarter 2026 dividend